{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:31:12Z","timestamp":1792139472561,"version":"4.4.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41585-025-01002-0","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T06:38:48Z","timestamp":1740551928000},"page":"509-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the effects of prostate cancer therapies on cardiovascular health"],"prefix":"10.1038","volume":"22","author":[{"given":"Steven","family":"Tisseverasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-7348","authenticated-orcid":false,"given":"Marwan","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bahoric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-5617","authenticated-orcid":false,"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamim","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"1002_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1311593","volume":"370","author":"A Bill-Axelson","year":"2014","unstructured":"Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370, 932\u2013942 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475\u2013487 (2007).","journal-title":"Lancet Oncol."},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","volume":"25","author":"DA Loblaw","year":"2007","unstructured":"Loblaw, D. A. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.\u00a0J. Clin. Oncol. 25, 1596\u20131605 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor, O. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 15, 738\u201346 (2014).","journal-title":"Lancet Oncol."},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513\u20131520 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"TM Beer","year":"2019","unstructured":"Beer T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/cancers14174149","volume":"14","author":"R Clark","year":"2022","unstructured":"Clark, R., Vesprini, D. & Narod, S. A. The effect of age on prostate cancer survival. Cancers 14, 4149 (2022).","journal-title":"Cancers"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon, K. M. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur. Heart J. 40, 3889\u20133897 (2019).","journal-title":"Eur. Heart J."},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/jnci\/djs299","volume":"104","author":"MM Epstein","year":"2012","unstructured":"Epstein, M. M., Edgren, G., Rider, J. R., Mucci, L. A. & Adami, H.-O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J. Natl Cancer Inst. 104, 1335\u20131342 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Van Hemelrijck","year":"2010","unstructured":"Van Hemelrijck, M. et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J. Clin. Oncol. 28, 3448\u20133456 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong, D. P. et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J. Urol. 203, 1109\u20131111 (2020).","journal-title":"J. Urol."},{"key":"1002_CR14","doi-asserted-by":"publisher","first-page":"555475","DOI":"10.3389\/fphar.2020.555475","volume":"11","author":"M Wilk","year":"2020","unstructured":"Wilk, M., Wa\u015bko-Grabowska, A. & Szmit, S. Cardiovascular complications of prostate cancer treatment. Front. Pharmacol. 11, 555475 (2020).","journal-title":"Front. Pharmacol."},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63\u201389 (2019).","journal-title":"World J. Oncol."},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1002\/cam4.1754","volume":"7","author":"D Schoormans","year":"2018","unstructured":"Schoormans, D. et al. Incidence of cardiovascular disease up to 13 year after cancer diagnosis: a matched cohort study among 32 757 cancer survivors. Cancer Med. 7, 4952\u20134963 (2018).","journal-title":"Cancer Med."},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"e0247919","DOI":"10.1371\/journal.pone.0247919","volume":"16","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Ten-year cardiovascular risk among cancer survivors: the National Health and Nutrition Examination Survey. PLoS ONE 16, e0247919 (2021).","journal-title":"PLoS ONE"},{"key":"1002_CR18","unstructured":"Marques, P. et al. Physiology of GnRH and gonadotrophin secretion. Endotext [Internet] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279070\/ (updated 15 October 2024)."},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating, N. L., O\u2019Malley, A. J., Freedland, S. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J. Natl Cancer Inst. 102, 39\u201346 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal, C. S. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110, 1493\u20131500 (2007).","journal-title":"Cancer"},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai, H. K., D\u2019Amico, A. V., Sadetsky, N., Chen, M.-H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516\u20131524 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine, G. N. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121, 833\u2013840 (2010).","journal-title":"Circulation"},{"key":"1002_CR23","unstructured":"Research Center for Drug Evaluation. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases (FDA, 2017)."},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith, M. R., Klotz, L., Persson, B.-E., Olesen, T. K. & Wilde, A. A. M. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J. Urol. 184, 2313\u20132319 (2010).","journal-title":"J. Urol."},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/cncr.33486","volume":"127","author":"SS Butler","year":"2021","unstructured":"Butler, S. S. et al. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: a secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. Cancer 127, 2213\u20132221 (2021).","journal-title":"Cancer"},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00432-020-03412-6","volume":"147","author":"DK Kim","year":"2021","unstructured":"Kim, D. K. et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. J. Cancer Res. Clin. Oncol. 147, 1217\u20131226 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1002_CR27","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen, P. L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359\u20132366 (2011).","journal-title":"JAMA"},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2018.07.2018","volume":"103","author":"JA Holmes","year":"2019","unstructured":"Holmes, J. A. et al. Cardiovascular preventive care and coordination of care in prostate cancer survivors: a multi-institutional prospective study. Int. J. Radiat. Oncol. Biol. Phys. 103, 112\u2013115 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(10)70063-2","volume":"11","author":"PJ Saylor","year":"2010","unstructured":"Saylor, P. J. & Fogerty, A. E. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncol. 11, 406\u2013407 (2010).","journal-title":"Lancet Oncol."},{"key":"1002_CR30","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith, M. R. et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer 112, 2188\u20132194 (2008).","journal-title":"Cancer"},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith, M. R., Lee, H. & Nathan, D. M. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 91, 1305\u20131308 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cyto.2010.11.011","volume":"53","author":"JG Cannon","year":"2011","unstructured":"Cannon, J. G., Kraj, B. & Sloan, G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine 53, 141\u2013144 (2011).","journal-title":"Cytokine"},{"key":"1002_CR33","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith, J. C. et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86, 4261\u20134267 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco, C. et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur. Urol. 68, 386\u2013396 (2015).","journal-title":"Eur. Urol."},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/js.2018-00039","volume":"2","author":"T Gagliano-Juc\u00e1","year":"2018","unstructured":"Gagliano-Juc\u00e1, T. et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J. Endocr. Soc. 2, 485\u2013496 (2018).","journal-title":"J. Endocr. Soc."},{"key":"1002_CR36","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1210\/en.2010-0663","volume":"151","author":"J Bourghardt","year":"2010","unstructured":"Bourghardt, J. et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 151, 5428\u20135437 (2010).","journal-title":"Endocrinology"},{"key":"1002_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mce.2017.10.006","volume":"465","author":"K Takov","year":"2018","unstructured":"Takov, K., Wu, J., Denvir, M. A., Smith, L. B. & Hadoke, P. W. F. The role of androgen receptors in atherosclerosis. Mol. Cell. Endocrinol. 465, 82\u201391 (2018).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","volume":"32","author":"SN Hopmans","year":"2014","unstructured":"Hopmans, S. N., Duivenvoorden, W. C. M., Werstuck, G. H., Klotz, L. & Pinthus, J. H. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol. Oncol. 32, 1126\u20131134 (2014).","journal-title":"Urol. Oncol."},{"key":"1002_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep26220","volume":"6","author":"A Knutsson","year":"2016","unstructured":"Knutsson, A. et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE\u2212\/\u2212 mice. Sci. Rep. 6, 26220 (2016).","journal-title":"Sci. Rep."},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/ATVBAHA.123.319426","volume":"44","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. FSH is responsible for androgen deprivation therapy-associated atherosclerosis in mice by exaggerating endothelial inflammation and monocyte adhesion. Arteriosclerosis Thrombosis Vasc. Biol. 44, 698\u2013719 (2024).","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"key":"1002_CR41","first-page":"187","volume":"73","author":"Z Poljak","year":"2018","unstructured":"Poljak, Z., Hulin, I., Maruscakova, L. & Mladosievicova, B. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 73, 187\u2013190 (2018).","journal-title":"Pharmazie"},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2010.02.113","volume":"394","author":"L Sun","year":"2010","unstructured":"Sun, L. et al. Further evidence for direct pro-resorptive actions of FSH. Biochem. Biophys. Res. Commun. 394, 6\u201311 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1002_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford, E. D. et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol. Oncol. 35, 183\u2013191 (2017).","journal-title":"Urol. Oncol."},{"key":"1002_CR44","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1210\/jc.2015-2237","volume":"100","author":"K Mohammed","year":"2015","unstructured":"Mohammed, K. et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 100, 4012\u20134020 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1530\/EJE-17-1072","volume":"178","author":"N Russell","year":"2018","unstructured":"Russell, N. et al. Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. Eur. J. Endocrinol. 178, 565\u2013576 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","volume":"397","author":"RE Langley","year":"2021","unstructured":"Langley, R. E. et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet 397, 581 (2021).","journal-title":"Lancet"},{"key":"1002_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000345423","volume":"90","author":"J Anderson","year":"2012","unstructured":"Anderson, J. et al. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol. Int. 90, 321\u2013328 (2012).","journal-title":"Urol. Int."},{"key":"1002_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"M Mason","year":"2013","unstructured":"Mason, M. et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin. Oncol. 25, 190\u2013196 (2013).","journal-title":"Clin. Oncol."},{"key":"1002_CR49","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","volume":"110","author":"K Axcrona","year":"2012","unstructured":"Axcrona, K. et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 110, 1721\u20131728 (2012).","journal-title":"BJU Int."},{"key":"1002_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1569-9056(13)60476-5","volume":"5","author":"B Tombal","year":"2012","unstructured":"Tombal, B. et al. P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer. Eur. Urol. Suppl. 5, 228 (2012).","journal-title":"Eur. Urol. Suppl."},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/j.juro.2014.02.2104","volume":"191","author":"D Crawford","year":"2014","unstructured":"Crawford, D., Shore, N., Higano, C., Neijber, A. & Yankov, V. PD27-05 Intermittent androgen deprivation with the gonadotrophin-releasing hormone antagonist degarelix. J. Urol. 191, e766 (2014).","journal-title":"J. Urol."},{"key":"1002_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen, P. C. et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol. 65, 565\u2013573 (2014).","journal-title":"Eur. Urol."},{"key":"1002_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","volume":"79","author":"M Abufaraj","year":"2021","unstructured":"Abufaraj, M. et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur. Urol. 79, 44\u201353 (2021).","journal-title":"Eur. Urol."},{"key":"1002_CR54","doi-asserted-by":"publisher","first-page":"e3845","DOI":"10.1097\/MD.0000000000003845","volume":"95","author":"A Sciarra","year":"2016","unstructured":"Sciarra, A. et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine 95, e3845 (2016).","journal-title":"Medicine"},{"key":"1002_CR55","doi-asserted-by":"crossref","unstructured":"Scailteux, L.-M., Naudet, F., Alimi, Q., Vincendeau, S. & Oger, E. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine 95, e3873 (2016).","DOI":"10.1097\/MD.0000000000003873"},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"276","DOI":"10.23736\/S2724-6051.20.03756-X","volume":"73","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis. Minerva Urol. Nephrol. 73, 276\u2013282 (2021).","journal-title":"Minerva Urol. Nephrol."},{"key":"1002_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","volume":"8","author":"F Cirne","year":"2021","unstructured":"Cirne, F. et al. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur. Heart J. Cardiovasc. Pharmacother. 8, 253\u2013262 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"1002_CR58","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore, N. D. et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl. J. Med. 382, 2187\u20132196 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR59","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.euo.2021.07.002","volume":"5","author":"R Sari Motlagh","year":"2021","unstructured":"Sari Motlagh, R. et al. The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. Eur. Urol. Oncol. 5, 138\u2013145 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1002_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","volume":"39","author":"P Davey","year":"2021","unstructured":"Davey, P. & Kirby, M. G. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J. Urol. 39, 307\u2013315 (2021).","journal-title":"World J. Urol."},{"key":"1002_CR61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/TCRM.S249208","volume":"16","author":"V Perrone","year":"2020","unstructured":"Perrone, V. et al. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther. Clin. Risk Manag. 16, 393\u2013401 (2020).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1002_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.03.002","volume":"77","author":"L-M Scailteux","year":"2017","unstructured":"Scailteux, L.-M. et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists \u2014 a nationwide population-based cohort study based on 2010\u20132013 French Health Insurance data. Eur. J. Cancer 77, 99\u2013108 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1002_CR63","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/ijc.33397","volume":"148","author":"G George","year":"2021","unstructured":"George, G. et al. Risk of cardiovascular disease following gonadotropin\u2010releasing hormone agonists vs antagonists in prostate cancer: real\u2010world evidence from five databases. Int. J. Cancer 148, 2203\u20132211 (2021).","journal-title":"Int. J. Cancer"},{"key":"1002_CR64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/EDE.0000000000001132","volume":"31","author":"CR Cardwell","year":"2020","unstructured":"Cardwell, C. R. et al. The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies. Epidemiology 31, 432\u2013440 (2020).","journal-title":"Epidemiology"},{"key":"1002_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fonc.2018.00543","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe, M. C. et al. Retrospective analysis of patients with prostate cancer initiating GnRH agonists\/antagonists therapy using a German claims database: epidemiological and patient outcomes. Front. Oncol. 8, 543 (2018).","journal-title":"Front. Oncol."},{"key":"1002_CR66","doi-asserted-by":"publisher","first-page":"e2130587","DOI":"10.1001\/jamanetworkopen.2021.30587","volume":"4","author":"JD Wallach","year":"2021","unstructured":"Wallach, J. D. et al. Real-world cardiovascular outcomes associated with degarelix vs leuprolide for prostate cancer treatment. JAMA Netw. Open\u00a04, e2130587 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1002_CR67","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes, R. D. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144, 1295\u20131307 (2021).","journal-title":"Circulation"},{"key":"1002_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ajur.2019.09.003","volume":"7","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Efficacy and safety of degarelix in patients with prostate cancer: results from a phase III study in China. Asian J. Urol. 7, 301\u2013308 (2020).","journal-title":"Asian J. Urol."},{"key":"1002_CR69","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jjco\/hys035","volume":"42","author":"S Ozono","year":"2012","unstructured":"Ozono, S. et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn. J. Clin. Oncol. 42, 477\u2013484 (2012).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"1002_CR70","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1111\/cas.13600","volume":"109","author":"S Ozono","year":"2018","unstructured":"Ozono, S. et al. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: a phase III study. Cancer Sci. 109, 1920\u20131929 (2018).","journal-title":"Cancer Sci."},{"key":"1002_CR71","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel, D. et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J. Urol. 202, 1199\u20131208 (2019).","journal-title":"J. Urol."},{"key":"1002_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S15850","volume":"6","author":"Y Rehman","year":"2012","unstructured":"Rehman, Y. & Rosenberg, J. E. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug. Des. Devel Ther. 6, 13\u201318 (2012).","journal-title":"Drug. Des. Devel Ther."},{"key":"1002_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"J Schalken","year":"2016","unstructured":"Schalken, J. & Fitzpatrick, J. M. Enzalutamide: targeting the androgen signalling pathway in metastatic castration\u2010resistant prostate cancer. BJU Int. 117, 215\u2013225 (2016).","journal-title":"BJU Int."},{"key":"1002_CR74","first-page":"501","volume":"10","author":"UJ Patel","year":"2019","unstructured":"Patel, U. J. & Caulfield, S. Apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. J. Adv. Pract. Oncol. 10, 501\u2013507 (2019).","journal-title":"J. Adv. Pract. Oncol."},{"key":"1002_CR75","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"K Fizazi","year":"2018","unstructured":"Fizazi, K., Smith, M. R. & Tombal, B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin. Genitourin. Cancer 16, 332\u2013340 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","volume":"39","author":"AK Morgans","year":"2021","unstructured":"Morgans, A. K. et al. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol. Oncol. 39, 52\u201362 (2021).","journal-title":"Urol. Oncol."},{"key":"1002_CR77","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/cancers15082316","volume":"15","author":"J Fradin","year":"2023","unstructured":"Fradin, J., Kim, F. J., Lu-Yao, G. L., Storozynsky, E. & Kelly, W. K. Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer. Cancers 15, 2316 (2023).","journal-title":"Cancers"},{"key":"1002_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone, E. B. et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide \u2014 a pharmacovigilance study. EClinicalMedicine 36, 100887 (2021).","journal-title":"EClinicalMedicine"},{"key":"1002_CR79","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41391-023-00757-0","volume":"27","author":"YHA Lee","year":"2023","unstructured":"Lee, Y. H. A. et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 27, 776\u2013782 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1002_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clgc.2021.08.009","volume":"20","author":"J Hu","year":"2022","unstructured":"Hu, J., Aprikian, A. G., Vanhuyse, M. & Dragomir, A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin. Genitourin. Cancer 20, 17\u201324 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR81","doi-asserted-by":"publisher","unstructured":"Matsukawa, A. et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-024-00886-0 (2024).","DOI":"10.1038\/s41391-024-00886-0"},{"key":"1002_CR82","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/cancers16183187","volume":"16","author":"W-A Kwon","year":"2024","unstructured":"Kwon, W.-A., Song, Y. S. & Lee, M.-K. Strategic advances in combination therapy for metastatic castration-sensitive prostate cancer: current insights and future perspectives. Cancers 16, 3187 (2024).","journal-title":"Cancers"},{"key":"1002_CR83","unstructured":"Cohagan, B. & Brandis, D. Torsade de Pointes. StatPearls [Internet] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459388\/ (updated 8 August 2023)."},{"key":"1002_CR84","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1758834016656493","volume":"8","author":"E Verzoni","year":"2016","unstructured":"Verzoni, E. et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther. Adv. Med. Oncol. 8, 323\u2013330 (2016).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1002_CR85","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli, R. et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin. Genitourin. Cancer 16, e645\u2013e653 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR86","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1016\/j.clgc.2019.07.001","volume":"17","author":"V Di Nunno","year":"2019","unstructured":"Di Nunno, V. et al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin. Genitourin. Cancer 17, e871\u2013e877 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR87","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji, O. et al. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 10, 874\u2013884 (2024).","journal-title":"JAMA Oncol."},{"key":"1002_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102066","volume":"22","author":"S Zhou","year":"2024","unstructured":"Zhou, S. et al. Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials. Clin. Genitourin. Cancer 22, 102066 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR89","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","volume":"6","author":"B Cao","year":"2023","unstructured":"Cao, B., Kim, M., Reizine, N. M. & Moreira, D. M. Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis. Eur. Urol. Oncol. 6, 237\u2013250 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1002_CR90","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408\u20131418 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR92","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380, 1235\u20131246 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR93","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389, 1453\u20131465 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR94","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1078-0432.CCR-11-1805","volume":"18","author":"MN Stein","year":"2012","unstructured":"Stein, M. N., Goodin, S. & DiPaola, R. S. Abiraterone in prostate cancer: a new angle to an old problem. Clin. Cancer Res. 18, 1848\u20131854 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1002_CR95","unstructured":"Dean, L. & Kane, M. in Medical Genetics Summaries (eds Pratt, V. M. et al.) (National Center for Biotechnology Information (US), 2012)."},{"key":"1002_CR96","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1124\/dmd.116.070672","volume":"44","author":"J Monbaliu","year":"2016","unstructured":"Monbaliu, J. et al. In vitro and in vivo drug\u2013drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug. Metab. Dispos. 44, 1682\u20131691 (2016).","journal-title":"Drug. Metab. Dispos."},{"key":"1002_CR97","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons, J. A. et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin. Pharmacokinet. 54, 1057\u20131069 (2015).","journal-title":"Clin. Pharmacokinet."},{"key":"1002_CR98","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","volume":"59","author":"I Duran","year":"2020","unstructured":"Duran, I. et al. Pharmacokinetic drug\u2013drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clin. Pharmacokinet. 59, 1135\u20131148 (2020).","journal-title":"Clin. Pharmacokinet."},{"key":"1002_CR99","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth, C. et al. Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies. Eur. J. Drug. Metab. Pharmacokinet. 44, 747\u2013759 (2019).","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."},{"key":"1002_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek, H. et al. Androgen receptor pathway inhibitors and drug\u2013drug interactions in prostate cancer. ESMO Open\u00a09, 103736 (2024).","journal-title":"ESMO Open"},{"key":"1002_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2221-5","volume":"16","author":"F Meng","year":"2016","unstructured":"Meng, F. et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16, 180 (2016).","journal-title":"BMC Cancer"},{"key":"1002_CR102","doi-asserted-by":"publisher","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao, J. et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE 9, e107516 (2014).","journal-title":"PLoS ONE"},{"key":"1002_CR103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0749-0704(18)30545-1","volume":"3","author":"SJ Barker","year":"1987","unstructured":"Barker, S. J., Gamel, D. M. & Tremper, K. K. Cardiovascular effects of anesthesia and operation. Crit. Care Clin. 3, 251\u2013268 (1987).","journal-title":"Crit. Care Clin."},{"key":"1002_CR104","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1161\/circ.105.10.1257","volume":"105","author":"Committee Members","year":"2002","unstructured":"Committee Members et al. ACC\/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery \u2014 executive summary a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Circulation 105, 1257\u20131267 (2002).","journal-title":"Circulation"},{"key":"1002_CR105","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.3390\/jcm12123979","volume":"12","author":"M Wani","year":"2023","unstructured":"Wani, M. et al. Venous thromboembolism (VTE) in post-prostatectomy patients: systematic review and meta-analysis. J. Clin. Med. 12, 3979 (2023).","journal-title":"J. Clin. Med."},{"key":"1002_CR106","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/medicina60010173","volume":"60","author":"C Siech","year":"2024","unstructured":"Siech, C. et al. Cardiovascular disease and chronic pulmonary disease increase the risk of short-term major postoperative complications after robotic-assisted radical prostatectomy. Medicina 60, 173 (2024).","journal-title":"Medicina"},{"key":"1002_CR107","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones, C. U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365, 107\u2013118 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR108","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid, A. et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur. Urol. 74, 432\u2013441 (2018).","journal-title":"Eur. Urol."},{"key":"1002_CR109","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1200\/jco.2007.25.18_suppl.5014","volume":"25","author":"M Bolla","year":"2007","unstructured":"Bolla, M. et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT \u2014 results of the randomized EORTC Phase III trial 22961. JCO 25, 5014\u20135014 (2007).","journal-title":"JCO"},{"key":"1002_CR110","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla, M. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11, 1066\u20131073 (2010).","journal-title":"Lancet Oncol."},{"key":"1002_CR111","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","volume":"16","author":"A Zapatero","year":"2015","unstructured":"Zapatero, A. et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 16, 320\u2013327 (2015).","journal-title":"Lancet Oncol."},{"key":"1002_CR112","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaccao.2020.08.011","volume":"2","author":"J Gong","year":"2020","unstructured":"Gong, J. et al. Reduced cardiorespiratory fitness and increased cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer. JACC CardioOncol. 2, 553\u2013563 (2020).","journal-title":"JACC CardioOncol."},{"key":"1002_CR113","unstructured":"Hufnagle, J. J., Andersen, S. N. & Maani, E. V. Radiation-induced cardiac toxicity StatPearls [Internet] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554453\/ (updated 29 May 2023)."},{"key":"1002_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592746","volume":"10","author":"Y Guo","year":"2020","unstructured":"Guo, Y. et al. Effects of radiotherapy or radical prostatectomy on the risk of long-term heart-specific death in patients with prostate cancer. Front. Oncol. 10, 592746 (2020).","journal-title":"Front. Oncol."},{"key":"1002_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1121872","volume":"13","author":"C Kjellstadli","year":"2023","unstructured":"Kjellstadli, C. et al. Cardiovascular outcomes after curative prostate cancer treatment: a population-based cohort study. Front. Oncol. 13, 1121872 (2023).","journal-title":"Front. Oncol."},{"key":"1002_CR116","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijcard.2013.03.133","volume":"168","author":"MC Todaro","year":"2013","unstructured":"Todaro, M. C. et al. Cardioncology: state of the heart. Int. J. Cardiol. 168, 680\u2013687 (2013).","journal-title":"Int. J. Cardiol."},{"key":"1002_CR117","doi-asserted-by":"publisher","unstructured":"Bendahou, H. et al. Cardiotoxicity due to docetaxel rare but it exists: about a case and literature review. J. Case Rep. Med. Hist. https:\/\/doi.org\/10.54289\/JCRMH2300105 (2023).","DOI":"10.54289\/JCRMH2300105"},{"key":"1002_CR118","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/heart.86.2.219","volume":"86","author":"M Shimoyama","year":"2001","unstructured":"Shimoyama, M., Murata, Y., Sumi, K.-I., Hamazoe, R. & Komuro, I. Docetaxel induced cardiotoxicity. Heart 86, 219\u2013219 (2001).","journal-title":"Heart"},{"key":"1002_CR119","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky, E. K. et al. Cardiac disturbances during the administration of taxol. JCO 9, 1704\u20131712 (1991).","journal-title":"JCO"},{"key":"1002_CR120","first-page":"130","volume":"117","author":"SG Arbuck","year":"1993","unstructured":"Arbuck, S. G. et al. A reassessment of cardiac toxicity associated with taxol. J. Natl Cancer Inst. Monogr. 117, 130 (1993).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"1002_CR121","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page","year":"2016","unstructured":"Page, R. L. et al. Drugs that may cause or exacerbate heart failure. Circulation 134, e32\u2013e69 (2016).","journal-title":"Circulation"},{"key":"1002_CR122","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose, M., Burgess, J. T., O\u2019Byrne, K., Richard, D. J. & Bolderson, E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front. Cell Dev. Biol. 8, 564601 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1002_CR123","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.3390\/cancers14235922","volume":"14","author":"A-J Inderjeeth","year":"2022","unstructured":"Inderjeeth, A.-J., Topp, M., Sanij, E., Castro, E. & Sandhu, S. Clinical application of poly(ADP-ribose) polymerase (PARP) inhibitors in prostate cancer. Cancers 14, 5922 (2022).","journal-title":"Cancers"},{"key":"1002_CR124","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A. & Ngoi, N. PARP inhibitors: enhancing efficacy through rational combinations. Br. J. Cancer 129, 904\u2013916 (2023).","journal-title":"Br. J. Cancer"},{"key":"1002_CR125","doi-asserted-by":"publisher","first-page":"e390876","DOI":"10.1200\/EDBK_390876","volume":"43","author":"M Friedlander","year":"2023","unstructured":"Friedlander, M., Lee, Y. C. & Tew, W. P. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am. Soc. Clin. Oncol. Educ. Book 43, e390876 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1002_CR126","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.esmoop.2023.101154","volume":"8","author":"A Palazzo","year":"2023","unstructured":"Palazzo, A. et al. Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open\u00a08, 101154 (2023).","journal-title":"ESMO Open"},{"key":"1002_CR127","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ygyno.2024.01.012","volume":"182","author":"W Chen","year":"2024","unstructured":"Chen, W. et al. Hypertension associated with niraparib in cancer patients: a pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials. Gynecol. Oncol. 182, 108\u2013114 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1002_CR128","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/jcm13051218","volume":"13","author":"J-Y Han","year":"2024","unstructured":"Han, J.-Y., Seo, Y.-E., Kwon, J.-H., Kim, J. H. & Kim, M. G. Cardioprotective effects of PARP inhibitors: a re-analysis of a meta-analysis and a real-word data analysis using the FAERS database. J. Clin. Med. 13, 1218 (2024).","journal-title":"J. Clin. Med."},{"key":"1002_CR129","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin. Cancer Res. 26, 2487\u20132496 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1002_CR130","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094\u20131108 (2023).","journal-title":"Lancet Oncol."},{"key":"1002_CR131","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291\u2013303 (2023).","journal-title":"Lancet"},{"key":"1002_CR132","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. JCO 41, 3339\u20133351 (2023).","journal-title":"JCO"},{"key":"1002_CR133","doi-asserted-by":"publisher","unstructured":"Tawagi, K., Schmolze, M., Nguyen, B., Laviana, A. & Reizine, N. PARP inhibitors in prostate cancer \u2014 understanding the current landscape. IJCCD https:\/\/doi.org\/10.53876\/001c.120988 (2024).","DOI":"10.53876\/001c.120988"},{"key":"1002_CR134","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","volume":"10","author":"CH Marshall","year":"2024","unstructured":"Marshall, C. H. et al. Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial. JAMA Oncol. 10, 1400\u20131408 (2024).","journal-title":"JAMA Oncol."},{"key":"1002_CR135","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2023.41.6_suppl.190","volume":"41","author":"MC Markowski","year":"2023","unstructured":"Markowski, M. C. et al. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. JCO 41, 190\u2013190 (2023).","journal-title":"JCO"},{"key":"1002_CR136","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","volume":"132","author":"SR Vazquez","year":"2018","unstructured":"Vazquez, S. R. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 132, 2230\u20132239 (2018).","journal-title":"Blood"},{"key":"1002_CR137","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue, C. J., Dal Molin, G. Z., Sood, A. K. & Coleman, R. L. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 20, e15\u2013e28 (2019).","journal-title":"Lancet Oncol."},{"key":"1002_CR138","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","volume":"22","author":"P Vinci","year":"2021","unstructured":"Vinci, P. et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int. J. Mol. Sci. 22, 11687 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1002_CR139","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","volume":"145","author":"CJ Beavers","year":"2022","unstructured":"Beavers, C. J. et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 145, e811\u2013e838 (2022).","journal-title":"Circulation"},{"key":"1002_CR140","doi-asserted-by":"publisher","first-page":"1649\u20131675","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin, M. A. C., Sonke, G. S., Beijnen, J. H. & Huitema, A. D. R. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin. Pharmacokinet. 61, 1649\u20131675 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"1002_CR141","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clgc.2019.11.017","volume":"18","author":"M-P Huynh-Le","year":"2020","unstructured":"Huynh-Le, M.-P., Shults, R. C., Connor, M. J. & Hattangadi-Gluth, J. A. Adverse events associated with radium-223 in metastatic prostate cancer: disproportionality analysis of FDA data reflecting worldwide utilization. Clin. Genitourin. Cancer 18, 192\u2013200.e2 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1002_CR142","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin, P. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 15, 1397\u20131406 (2014).","journal-title":"Lancet Oncol."},{"key":"1002_CR143","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/a-1332-8230","volume":"60","author":"E Jafari","year":"2021","unstructured":"Jafari, E., Amini, A. L., Ahmadzadehfar, H., Bagheri, D. & Assadi, M. Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors. Nuklearmedizin 60, 99\u2013105 (2021).","journal-title":"Nuklearmedizin"},{"key":"1002_CR144","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1002_CR145","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever, M. A. & Higano, C. S. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520\u20133526 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1002_CR146","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff, D. C. et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. Circulation 129, S49\u2013S73 (2014).","journal-title":"Circulation"},{"key":"1002_CR147","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.286.2.180","volume":"286","author":"RB D\u2019Agostino Sr","year":"2001","unstructured":"D\u2019Agostino, R. B. Sr, Grundy, S., Sullivan, L. M. & Wilson, P. & for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286, 180\u2013187 (2001).","journal-title":"JAMA"},{"key":"1002_CR148","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357, j2099 (2017).","journal-title":"BMJ"},{"key":"1002_CR149","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 149, 430\u2013449 (2024).","journal-title":"Circulation"},{"key":"1002_CR150","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia, N. et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation 133, 537\u2013541 (2016).","journal-title":"Circulation"},{"key":"1002_CR151","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531\u20131538 (2008).","journal-title":"BJU Int."},{"key":"1002_CR152","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/jco.2015.33.7_suppl.151","volume":"33","author":"CS Higano","year":"2015","unstructured":"Higano, C. S. et al. Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial. JCO 33, 151\u2013151 (2015).","journal-title":"JCO"},{"key":"1002_CR153","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14737140.2018.1419871","volume":"18","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert. Rev. Anticancer. Ther. 18, 193\u2013198 (2018).","journal-title":"Expert. Rev. Anticancer. Ther."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01002-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:24:35Z","timestamp":1757143475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":153,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01002-0","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"10 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T. receives honoraria and consulting fees from Tolmar, AbbVie, Knight, Bayer, Janssen\u00a0and Sumitomo pharma. M.T. receives honoraria and consulting fees from AbbVie, Tersera\u00a0and Knight. F.S. has grants\/contracts with Janssen, Bayer, Merck, Pfizer, Astellas, BMS, Novartis, Sanofi\u00a0and AstraZeneca; receives consulting fees from Janssen, Bayer, Astellas, Novartis, Sanofi, AstraZeneca, Merck, Pfizer, Somitomo\u00a0and Tolmar; and\u00a0receives honoraria from Janssen, Bayer, Somitomo, Astellas, Novartis, Sanofi, AstraZeneca, Merck, Pfizer\u00a0and Tolmar. T.N. has grants\/contracts with Bayer, Jansen, Astellas, Tersera\u00a0and Sanofi Canada; receives consulting fees from AbbVie, Astellas, Jansen, Tersera, Tolmar, Bayer, AAA, Pfizer, Knight, AstraZeneca\u00a0and Sumitomo pharma; receives support for attending meetings\/travel from Jansen, Tolmar, Knight\u00a0and Bayer; and\u00a0is the chair of the Quebec GU Radiation oncology group and co-chair of the Canadian GU radiation oncology group. B.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}